Nasal polyposis: From cytokines to growth

American Journal of Rhinology

Volumn 14, Issue 5, 2000, Pages 279-290

  Bachert, Claus ^a   Gevaert, Philippe ^a   Holtappels, Gabriele ^a   Cuvelier, Claude ^a   Van Cauwenberge, Paul ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CORTICOSTEROID; EOSINOPHIL CATIONIC PROTEIN; EOTAXIN; FIBRONECTIN; GLUCOCORTICOID; HYALURONIC ACID; INTERLEUKIN 5; LEUKOTRIENE; TRANSFORMING GROWTH FACTOR BETA1;

ALLERGIC RHINITIS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE RELEASE; EOSINOPHILIA; HUMAN; HUMAN TISSUE; INFLAMMATION; NOSE POLYP; PATHOGENESIS; POLYPECTOMY;

EID: 0033764445     PISSN: 10506586     EISSN: None     Source Type: Journal    
DOI: 10.2500/105065800781329573     Document Type: Conference Paper

References (58)

1. van der Baan B. Epidemiology and natural history. In Nasal Polyposis: An Inflammatory Disease and its Treatment. Mygind N. and Lildholdt T (Eds). Copenhagen: Munksgaard, 13-16, 1997.
2. Mygind N, and Lildholdt T. Nasal Polyposis: An Inflammatory Disease and its Treatment. Copenhagen: Munksgaard, 1997.
3. Caplin I, Haynes TJ, and Sphan J. Are nasal polyps an allergic phenomenon? Ann Allergy 29:631-634, 1971.
4. Settipane GA. Epidemiology of nasal polyps. Allergy Asthma Proc 17:231-236, 1996.
5. Settipane GA. Nasal polyps: pathology, immunology and treatment. Am J Rhinol 1:119-126, 1987.
6. Woakes E. Uber nekrotisierende Ethmoiditis und ihre Beziehung zur Entwicklung von Nasenpolypen. Br Med J 4:701-705, 1885.
7. Eggston AA, and Wolff D. Histopathology of Ear, Nose, and Throat. Baltimore: Williams & Wilkins, 1947.
8. Tos M, and Mogensen C. Pathogenesis of nasal polyps. Rhinology 15:87-95, 1977.
9. Krajina Z. A contribution to the aethiopathogenesis of nasal polyps. Pract Otorhinolaryngol 25:241-246, 1963.
10. Bernstein JM, and Yankaskas JR. Increased ion transport in cultured nasal polyp epithelial cells. Arch Otolaryngol Head Neck Surg 120:993-996, 1994.
11. Caye-Thomasen P, Hermansson A, Tos M, and Prellner K. Polyp pathogenesis - a histopathological study in experimental otitis media Acta Otolaryngol (Stockh) 115:76-82, 1995.
12. Larsen PL, Tos M, Kuijpers W. and van der Beek JM. The early stages of polyp formation. Laryngoscope 102:670-677, 1992.
13. Norlander T, Westrin KM, Fukami M, et al. Experimentally induced polyps in the sinus mucosa: a structural analysis of the initial stages Laryngoscope 106:196-203, 1996.
14. Bachert C, Wagenmann M, Hauser U, and Rudack C. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol 99:837-842, 1997.
15. Sorensen H, Mygind N, Tygstrup I, and Winge FE. Histology of nasal polyps of different etiology. Rhinology 15:121-128, 1977.
16. Drake-Lee AB, Chevreton E, and Lowe D. The effects of different fixations on the distribution and numbers of mast cells in patients with nasal polyps. J Laryngol Otol 102:1099-1101, 1988.
17. Drake-Lee A, and Price J. Mast cell ultrastructure in the inferior turbmate and stroma of nasal polyps. J Laryngol Otol 111:340-345, 1997.
18. Wang QP, Escudier E, Roudot-Thoraval F, et al. Myofibroblast accumulation induced by transforming growth factor-beta is involved in the pathogenesis of nasal polyps. Laryngoscope 107: 926-931, 1997.
19. Walsh GM, Symon FA, and Wardlaw AJ. Human eosinophils preferentially survive on tissue fibronectin compared with plasma fibronectin. Clin Exp Allergy 25:1128-1136, 1995.
20. Nakagawa T, Yamane H, Shigeta T, et al. Interaction between fibronectin and eosinophils in the growth of nasal polyps. Laryngoscope 109:557-561, 1999.
21. Greiff L, Erjefalt J, Andersson M, et al. Microvascular exudation of plasma and epithelial shedding-restitution processes as causative events in inflammatory airway diseases. In Nasal Polyposis: An Inflammatory Disease and its Treatment. Mygind N, and Lildholdt T (Eds). Copenhagen: Munksgaard, 50-60, 1997.
22. Levi-Schaffer F, Garbuzenko E, Rubin A, et al. Human eosinophils regulate human lung- and skin-derived fibroblast properties in vitro: A role for transforming growth factor beta (TGF-beta). Proc Natl Acad Sci USA 96:9660-9665, 1999.
23. Minnicozzi M, Duran WN, Gleich GJ, and Egan RW. Eosinophil granule proteins increase microvascular macromolecular transport in the hamster cheek pouch. J Immunol 153:2664-2670, 1994.
24. Biewenga J, Stoop AE, van der Heijden HA, et al. Albumin and immunoglobulin levels in nasal secretions of patients with nasal polyps treated with endoscopic sinus surgery and topical corticosteroids. J Allergy Clin Immunol 96:334-340, 1995.
25. Persson CG. Plasma exudation in the airways: mechanisms and function. Eur Respir J 4:1268-1274, 1991.
26. Mould AW, Matthaei KI, Young IG, and Foster PS. Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice. J Clin Invest 99:1064-1071, 1997.
27. Jahnsen FL, Haye R, Gran E, et al. Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 i, and monocyte-chemotactic protein-4 in human airway inflammation with eosinophilia. J Immunol 163:1545-1551, 1999.
28. Ying S, Robinson DS, Meng Q, et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 27:3507-3516, 1997.
29. Beck LA, Stellato C, Beall LD, et al. Detection of the chemokine RANTES and endothelial adhesion molecules in nasal polyps. J Allergy Clin Immunol 98:766-780, 1996.
30. Dibbert B, Daigle I, Braun D, et al. Role for Bcl-xL in delayed eosinophil apoptosis mediated by granulocyte-macrophage colony-stimulating factor and interleukin-5. Blood 92:778-783, 1998.
31. Simon HU, Yousefi S, Schranz C, et al. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 158:3902-3908, 1997.
32. Bachert C, Hauser U, Wagenmann M, et al. Interleukin-5 protein is detected in nasal polyps. J Allergy Clin Immunol 95:389, 1995. (Abstract).
33. Bachen C, Wagenmann M, Rudack C, et al. The role of cytokines in infectious sinusitis and nasal polyposis. Allergy 53:2-13, 1998.
34. Tavemier J, Plaetinck G, Guisez Y, et al. The role of interleukin 5 in the production and function of eosinophils. In Blood Cell Biochemistry. Whetton AD, Gordon J (Eds). New York: Plenum Press, 321-361, 1996.
35. Salvi S, Semper A, Blomberg A, et al. Interleukin-5 production by human airway epithelial cells. Am J Respir Cell Mol Biol 20:984-991, 1999.
36. Minshall EM, Leung DY, Martin RJ, et al. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 17:326-333, 1997.
37. Coste A, Lefaucheur JP, Wang QP, et al. Expression of the transforming growth factor beta isoforms in inflammatory cells of nasal polyps. Arch Otolarynaol Head Neck Surg 124:1361-1366, 1998.
38. Eisma RJ, Allen JS, Lafreniere D, et al. Eosinophil expression of transforming growth factor-beta and its receptors in nasal polyposis: role of the cytokines in this disease process. Am J Otolaryngol 18:405-411, 1997.
39. Elovic A, Wong DT, Weller PF, et al. Expression of transforming growth factors-alpha and beta 1 messenger RNA and product by eosinophils in nasal polyps. J Allergy Clin Immunol 93:864-869, 1994.
40. Ohno I, Lea RG, Flanders KC, et al. Eosinophils in chronically inflamed human upper airway tissues express transforming growth factor beta 1 gene (TGF beta 1). J Clin Invest 89:1662-1668, 1992.
41. Gevaert P, Bachert C, and Van Cauwenberge P. The role of IL-5 and TGF-beta1 in eosinophilic inflammation in nasal polyps. J Allergy Clin Immunol 105:S72, 2000 (Abstract).
42. Alam R, Forsythe P, Stafford S, and Fukuda Y. Transforming growth factor beta abrogates the effects of hematopoietins on eosinophils and induces their apoptosis. J Exp Med 179:1041-1045, 1994.
43. Luttmann W, Franz P, Matthys H, and Virchow JCJ. Effects of TGF-beta on eosinophil chemotaxis. Scand J Immunol 47:127-130, 1998.
44. Holmberg K, Juliusson S, Balder B, et al. Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis. Ann Allergy Asthma Immunol 78:270-276, 1997.
45. Lildholdt T, Runderantz H, Bende M, and Larven K, Glucocorticoid treatment for nasal polyps. The use of topical budesonide powder, intramuscular betamethasone, and surgical treatment. Arch Otolaryngol Head Neck Surg 123:595-600, 1997.
46. Lund VJ, Flood J, Sykes AP, and Richards DH Effect of fluticasone in severe polyposis. Arch Otolaryngol Head Neck Surg 124:515-518, 1998.
47. Mygind N, and Lildholdt T. Nasal polyps treatment: medical management. Allergy Asthma Proc 17:275-282, 1996.
48. Ruhno J, Andersson B, Denburg J, et al. A double-blind comparison of intranasal budesonide with placebo for nasal polyposis. J Allergy Clin Immunol 86:946-953, 1990.
49. Tos M, Svendstrup F, Arndal H, et al. Efficacy of an aqueous and a powder formulation of nasal budesonide compared in patients with nasal polyps. Am J Rhinol 12:183-189, 1998.
50. Vendelo JL, Illum P, Kristensen S, et al. The effect of budesonide (Rhinocort) in the treatment of small and medium-sized nasal polyps. Clin Otolaryngol 18:524-527, 1993.
51. van Camp C. and Clement PA. Results of oral steroid treatment in nasal polyposis. Rhinology 32:5-9, 1994.
52. Hamilos DL, Thawley SE, Kramper MA, et al. Effect of intranasal fluticasone on cellular infiltration, endothelial adhesion molecule expression, and proinflammatory cytokine mRNA in nasal polyp disease. J Allergy Clin Immunol 103: 79-87, 1999.
53. Kanai N, Denburg J, Jordana M, and Dolovich J. Nasal polyp inflammation. Effect of topical nasal steroid. Am J Respir Crit Care Med 150:1094-1100, 1994.
54. Mullol J, Xaubet A, Lopez E, et al. Comparative study of the effects of different glucocorticosteroids on eosinophil survival primed by cultured epithelial cell supernatants obtained from nasal mucosa and nasal polyps. Thorax 50:270-274, 1995.
55. Tingsgaard PK, Bock T, Larsen PL, and Tos M. Topical budesonide treatment reduces endothelial expression of intercellular adhesion molecules (vascular cell adhesion molecule-1 and P-selectin) and eosinophil infiltration in nasal polyps. Acta Otolaryngol (Stockh) 119:362-368, 1999.
56. Hamilos DL, Thawley SE, Kramper MA, et al. Effect of intranasal fluticasone on cellular infiltration, endothelial adhesion molecule expression, and proinflammatory cytokine mRNA in nasal polyp disease. J Allergy Clin Immunol 103:79-87, 1999.
57. Tingsgaard PK, Larsen PL, Bock T, et al Expression of intercellular adhesion molecule-1 on the vascular endothelium in nasal polyps before, during and after topical glucocorticoid treatment Acta Otolaryngol (Stockh) 118:404-408, 1998.
58. Jahnsen FL, Haye R, Gran E, et al. Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 1, and monocyte-chemotactic protein-4 in human airway inflammation with eosinophilia. J Immunol 163:1545-1551, 1999.